Browsing Tag
Oncology
318 posts
BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food…
March 28, 2021
French biotech company Step Pharma raises €35m in a Series B round
Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1…
March 24, 2021
Aura Biosciences raises $80m for VDC therapies for cancers
Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round…
March 22, 2021
Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy
Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T…
March 22, 2021
Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab
Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech…
March 4, 2021
Agilent Technologies to acquire Resolution Bioscience in $695m worth deal
Agilent Technologies, a US analytical instrumentation development and manufacturing company, has agreed to acquire Resolution Bioscience in a…
March 2, 2021
ForDoz Pharma to manufacture LipoMedix’ oncology candidate Promitil
New Jersey-based ForDoz Pharma has signed an agreement with LipoMedix for manufacturing the latter’s lead compound – pegylated…
February 19, 2021
Targovax’s ONCOS-102 receives FDA fast track designation for malignant pleural mesothelioma treatment
In a significant development for cancer treatment, Targovax, a Norwegian biotech firm specializing in immune-oncology, has announced that…
February 15, 2021
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb’s Opdivo (nivolumab)…
January 26, 2021
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.
December 19, 2020